CHF6001 DPI
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CHF6001 DPI, covering 2026-02-02 to 2026-02-02. Get the full timeline:
Most recent: Clinical Trial Update: A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) [Phase 3]